Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity-Reference-Cited by-同舟云学术

Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity

Published:2015-10-13 Issue:11 Volume:13 Page:1989-1998
ISSN:1538-7933
Container-title:Journal of Thrombosis and Haemostasis
language:en
Short-container-title:J Thromb Haemost

Author:

Mahlangu J. N.¹,Weldingh K. N.²,Lentz S. R.³,Kaicker S.⁴,Karim F. A.⁵,Matsushita T.⁶,Recht M.⁷,Tomczak W.⁸,Windyga J.⁹,Ehrenforth S.²,Knobe K.²,

Affiliation:

1. Haemophilia Comprehensive Care Centre; Faculty of Health Sciences; University of the Witwatersrand and National Health Laboratory Service; Johannesburg South Africa

2. Novo Nordisk A/S; Bagsvaerd Denmark

3. Department of Internal Medicine; University of Iowa Carver College of Medicine; Iowa City IA USA

4. Maimonides Medical Centre; New York NY USA

5. Haemophilia Centre; National Blood Centre; Kuala Lumpur Malaysia

6. Department of Transfusion Medicine; Nagoya University Hospital; Nagoya Japan

7. Hemophilia Center; Oregon Health and Science University; Portland OR USA

8. Department of Hematooncology and Bone Marrow Transplantation; Medical University of Lublin; Lublin Poland

9. Department of Disorders of Haemostasis and Internal Medicine; Institute of Hematology and Transfusion Medicine; Warsaw Poland

Funder

Novo Nordisk

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/jth.13141/fullpdf

Reference28 articles.

1. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors;Abshire;J Thromb Haemost,2004

2. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study;Astermark;Blood,2007

3. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial;Kavakli;Thromb Haemost,2006

4. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry;Parameswaran;Haemophilia,2005

5. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison;Young;Haemophilia,2008

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Site-directed mutagenesis of tissue factor pathway inhibitor–binding exosite D60A on factor VII results in a new factor VII variant with lower coagulant activity;Research and Practice in Thrombosis and Haemostasis;2024-01

2. Recombinant Coagulation Factors and Thrombolytic Agents;Pharmaceutical Biotechnology;2024

3. The MHC Associated Peptide Proteomics assay is a useful tool for the non-clinical assessment of immunogenicity;Frontiers in Immunology;2023-10-16

4. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

5. Preclinical risk assessment strategy to mitigate the T-cell dependent immunogenicity of protein biotherapeutics: State of the art, challenges and future perspectives;Journal of Pharmaceutical and Biomedical Analysis;2023-09